SLDB

6.90

4.56% -0.33

시간 외 거래: 6.89 -0.01 -0.14%

솔리드 바이오 (SLDB)

개요 뉴스 가격 이력 옵션 체인 Financials SLDB 왜 하락? 토론 예측 주식 분할

전일 마감가:

$7.23

열려 있는:

$7.36

하루 거래량:

1.42M

Relative Volume:

1.10

시가총액:

$679.05M

수익:

$14.79M

순이익/손실:

$-174.33M

주가수익비율:

-3.4126

EPS:

-2.0219

순현금흐름:

$-157.44M

1주 성능:

-7.38%

1개월 성능:

-7.88%

6개월 성능:

+75.57%

1년 성능:

+63.12%

1일 변동 폭

$6.7616

$7.48

1주일 범위

$6.7616

$7.535

52주 변동 폭

$2.41

$8.8661

솔리드 바이오 Stock (SLDB) Company Profile

명칭

Solid Biosciences Inc

부문

Healthcare (1106)

산업

Biotechnology (615)

전화

617-337-4680

주소

500 RUTHERFORD AVENUE, CHARLESTOWN, MA

직원

121

트위터

@SolidBioDMD

다음 수익 날짜

2026-05-21

최신 SEC 제출 서류

SLDB's Discussions on Twitter

Compare SLDB vs VRTX, REGN, ARGX, ALNY, ONC

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
SLDB Solid Biosciences Inc	6.90	711.53M	14.79M	-174.33M	-157.44M	-2.0219
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

솔리드 바이오 Stock (SLDB) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2026-03-20	개시	Guggenheim	Buy
2025-12-04	개시	Needham	Buy
2025-06-26	개시	Citigroup	Buy
2025-01-08	개시	Truist	Buy
2024-12-13	개시	Wedbush	Outperform
2024-12-10	개시	JMP Securities	Mkt Outperform
2024-07-15	업그레이드	JP Morgan	Neutral → Overweight
2024-06-24	업그레이드	Leerink Partners	Market Perform → Outperform
2024-05-31	재개	Piper Sandler	Overweight
2024-03-28	개시	William Blair	Outperform
2024-03-15	개시	Citigroup	Buy
2024-03-14	업그레이드	Piper Sandler	Neutral → Overweight
2023-12-08	개시	H.C. Wainwright	Buy
2021-07-12	개시	Piper Sandler	Neutral
2021-05-27	개시	Jefferies	Buy
2021-03-16	업그레이드	SVB Leerink	Mkt Perform → Outperform
2021-03-09	개시	Barclays	Overweight
2021-01-08	업그레이드	Credit Suisse	Underperform → Neutral
2020-07-28	다운그레이드	SVB Leerink	Outperform → Mkt Perform
2020-05-07	다운그레이드	Evercore ISI	Outperform → In-line
2019-10-11	개시	Evercore ISI	Outperform
2019-08-29	다운그레이드	Citigroup	Neutral → Sell
2019-08-19	업그레이드	SVB Leerink	Mkt Perform → Outperform
2019-08-16	업그레이드	Chardan Capital Markets	Neutral → Buy
2019-05-14	다운그레이드	Credit Suisse	Neutral → Underperform
2019-05-14	다운그레이드	Goldman	Neutral → Sell
2019-02-08	업그레이드	Citigroup	Sell → Neutral
2019-02-08	다운그레이드	SVB Leerink	Outperform → Mkt Perform
2018-11-06	개시	Citigroup	Sell
2018-09-06	개시	Credit Suisse	Neutral

모두보기

솔리드 바이오 주식(SLDB)의 최신 뉴스

May 05, 2026

Invus and affiliates hold 9.99% of Solid Biosciences (NASDAQ: SLDB) via warrants and shares - Stock Titan

May 05, 2026

May 01, 2026

One new Solid Biosciences employee gets 8,070 stock units - Stock Titan

May 01, 2026

Apr 30, 2026

Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy - marketscreener.com

Apr 30, 2026

Solid Biosciences receives EU orphan drug status for SGT-003 By Investing.com - Investing.com South Africa

Apr 28, 2026

Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy - The Manila Times

Apr 28, 2026

EU grants orphan status to Solid’s Duchenne gene therapy candidate - Stock Titan

Apr 28, 2026

Solid Biosciences Announces Receipt of European Commission - GlobeNewswire

Apr 28, 2026

Solid Biosciences (NASDAQ:SLDB) Rating Increased to Strong-Buy at Truist Financial - MarketBeat

Apr 28, 2026

Apr 27, 2026

BlackRock (NASDAQ: SLDB) holds 4.7% of Solid Biosciences, 4.58M shares - Stock Titan

Apr 27, 2026

Solid Biosciences Inc. sponsors SADS Foundation symposium to back genetic heart rhythm research - Traders Union

Apr 27, 2026

Solid Biosciences announces $240 million private placement - MSN

Apr 27, 2026

Apr 24, 2026

Solid Biosciences Inc. commits to industry and advocacy collaboration on Duchenne - Traders Union

Apr 24, 2026

Apr 23, 2026

Solid Biosciences (NASDAQ: SLDB) seeks approval to double authorized shares at 2026 meeting - Stock Titan

Apr 23, 2026

Apr 21, 2026

Solid Biosciences (SLDB) COO earns 79,341 RSUs on performance milestone - Stock Titan

Apr 21, 2026

Solid Biosciences (NASDAQ: SLDB) CMO awarded 58,847 RSUs on milestone - Stock Titan

Apr 21, 2026

Solid Biosciences (SLDB) CEO earns 169,401 RSUs tied to PSUs - Stock Titan

Apr 21, 2026

Solid Biosciences (SLDB) CTO earns 54,925 RSUs on performance milestone - Stock Titan

Apr 21, 2026

Solid Biosciences (SLDB) CFO awarded 56,647 RSUs after performance milestone - Stock Titan

Apr 21, 2026

Solid Biosciences (NASDAQ: SLDB) awards 54,925 performance-based RSUs - Stock Titan

Apr 21, 2026

Piper Sandler Reaffirms Their Buy Rating on Solid Biosciences (SLDB) - The Globe and Mail

Apr 21, 2026

Solid Biosciences Inc. advances SGT-212 gene therapy for Friedreich ataxia into human trials - Traders Union

Apr 21, 2026

Apr 20, 2026

Piper Sandler Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $17 - Moomoo

Apr 20, 2026

Solid Biosciences Inc. to present new targeting strategies in gene therapy - Traders Union

Apr 20, 2026

Apr 19, 2026

Solid Biosciences (NASDAQ:SLDB) Downgraded to Sell Rating by Wall Street Zen - MarketBeat

Apr 19, 2026

Apr 18, 2026

Who Backs Solid Biosciences (SLDB) Stock (Modest Uptick) 2026-04-18Index Investing - Cổng thông tin điện tử Tỉnh Sơn La

Apr 18, 2026

Apr 17, 2026

Solid Biosciences Inc. (NASDAQ:SLDB) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Apr 17, 2026

Apr 16, 2026

Analysts Are Bullish on These Healthcare Stocks: Stryker (SYK), Solid Biosciences (SLDB) - The Globe and Mail

Apr 16, 2026

Apr 15, 2026

Needham Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $19 - Moomoo

Apr 15, 2026

Apr 14, 2026

Solid Biosciences (NASDAQ:SLDB) Sets New 12-Month HighHere's What Happened - MarketBeat

Apr 14, 2026

Apr 13, 2026

SLDB: Guggenheim Initiates Coverage with a 'Buy' Rating at $26 | - GuruFocus

Apr 13, 2026

Dow Update: Is Solid Biosciences Inc part of any ETF2026 Pullbacks & Low Risk Entry Point Guides - baoquankhu1.vn

Apr 13, 2026

Solid Biosciences (NASDAQ:SLDB) Stock Price Down 3.9%Here's Why - MarketBeat

Apr 13, 2026

Sell Signal: Can Solid Biosciences Inc maintain its current growth rate2026 Short Interest & Fast Moving Trade Plans - baoquankhu1.vn

Apr 13, 2026

Apr 11, 2026

Solid Biosciences reclassifies board member Ilan Ganot to Class I director - Investing.com Australia

Apr 11, 2026

Solid Biosciences Inc. Files Form 8-K with SEC Detailing Company Information and No Amendments as of April 10, 2026 - Minichart

Apr 11, 2026

Solid Biosciences (NASDAQ:SLDB) Raised to "Hold" at Wall Street Zen - MarketBeat

Apr 11, 2026

Apr 10, 2026

Solid Biosciences reclassifies board member Ilan Ganot to Class I director By Investing.com - Investing.com Australia

Apr 10, 2026

Solid Biosciences Adjusts Board Classes in Governance Move - TipRanks

Apr 10, 2026

Solid Biosciences (NASDAQ: SLDB) asks shareholders to double authorized shares to 480,000,000 - Stock Titan

Apr 10, 2026

Board reshuffle at Solid Biosciences (NASDAQ: SLDB) balances director classes - Stock Titan

Apr 10, 2026

Activity Recap: Can Solid Biosciences Inc maintain its current growth rateOil Prices & Long-Term Safe Return Strategies - baoquankhu1.vn

Apr 10, 2026